Oaktree Acquisition Corp. III Life Sciences prices $175M IPO at $10/unit

Oaktree Acquisition Corp. III Life Sciences

Gross proceeds of $175M from 17.5M units at $10.00 each; units trade on Nasdaq as OACCU.
Each unit comprises one Class A share and 1/5 redeemable warrant exercisable at $11.50.
Underwriters have 45-day over-allotment option for up to 2.625M additional units.
Sponsor purchased 550,000 private placement units at $10 each, generating $5.5M.
Net proceeds held in trust for initial business combination; 24-month deadline to complete.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Oaktree Acquisition Corp. III Life Sciences: Adopted Amended and Restated Memorandum and Articles of Association in connection with IPO (effective 2024-10-23).

Change: charter amendment
Effective: 2024-10-23

Exact text from the filing

On October 23, 2024 and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Oaktree Acquisition Corp. III Life Sciences filing history →

Source: SEC EDGAR

accession 0001193125-24-244185

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.